An in-depth look to Kyverna Therapeutics, Inc. operating, investing, and financing activities

KYTX free cash flow for Q1 24 is -26.07 M USD. For 2023, KYTX free cash flow was -53.03 M USD and operating cash flow was -52.41 M USD.